Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of October 31, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 6,025,168,221 Ordinary shares of 25p each.
- Treasury Shares: 471,314,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,553,854,063.
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a statutory notification intended to assist shareholders in calculating disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,553,854,063) against the latest shareholder register.
- Confirm the number of shares held in Treasury (471,314,158) to ensure accurate calculation of free float.
- Check subsequent filings for any changes in share capital or treasury holdings since October 31, 2007.